FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Rapid communications in mass spectrometry : RCM2020; 34(23); e8920; doi: 10.1002/rcm.8920

Doping control analysis of GW1516 in equine plasma using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry.

Abstract: GW1516 is a peroxisome proliferator-activated receptor-δ agonist in the class of hormones and metabolic modulators. The use of GW1516 is banned in both horseracing and equestrian competitions. To the best of our knowledge, this is the first metabolic study of GW1516 in horses. Methods: After protein precipitation of pre- and post-administration plasma GW1516 samples, the supernatants were analyzed using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry to detect GW1516 and its metabolites. Monoisotopic ions of GW1516 and its metabolites were monitored from the full-scan mass spectral data of pre- and post-administration samples. Quantification methods were developed and validated to establish the elimination profiles of GW1516, its sulfoxide, and its sulfone in equine plasma. Results: GW1516 and its four metabolites GW1516 sulfoxide, GW1516 sulfone, 5-(hydroxymethyl)-4-methyl-2-(4-trifluoromethylphenyl)thiazole (HMTT), and M1 were detected in post-administration plasma samples. GW1516 sulfoxide, GW1516 sulfone, and HMTT were identified by comparison with their respective reference standards whereas M1 was tentatively identified as 4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carboxylic acid by mass spectral interpretation. GW1516 had the longest detection time in post-administration plasma. The elimination profiles of GW1516, its sulfoxide, and its sulfone in plasma were established. Conclusions: For the purpose of doping control, GW1516 is recommended as the target analyte to be monitored in equine plasma due to its long detection time (around 1 week) and the ready availability of its reference material.
© 2020 John Wiley & Sons, Ltd.
Get Full Text
Publication Date: 2020-08-11 PubMed ID: 32776613DOI: 10.1002/rcm.8920Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research presents a method to detect GW1516, a banned substance in horse racing and equestrian competitions, in horse plasma. The study utilized liquid chromatography and high-resolution mass spectrometry to identify GW1516 and its metabolites. The detection method was developed and validated, presenting the elimination profiles of the substance and its metabolites in horse plasma.

Objective of the Study

  • This research intended to develop a method for monitoring and detection of GW1516, a substance prohibited in equestrian sports, in horse plasma.
  • The objective also included determining GW1516’s metabolites and their respective elimination profiles in horse plasma after adminstration.

Methodology

  • Pre and post-administration plasma samples were treated with protein precipitation. Afterward, the supernatants were analyzed using liquid chromatography / electrospray ionization Q-Exactive high-resolution mass spectrometry to identify GW1516 and its subsequent metabolites.
  • Monoisotopic ions of GW1516 and its metabolites were monitored from the full-scan mass spectral data of the samples taken before and after administration.
  • A quantification method was developed and validated to establish elimination profiles of GW1516 and its two specific metabolites (sulfoxide and sulfone) in horse plasma.

Results

  • The research successfully detected GW1516 and its four metabolites in the plasma samples taken after administration.
  • Three of the metabolites (sulfoxide, sulfone, and HMTT) were identified through comparison with their reference standards. The fourth metabolite, M1, was tentatively identified as 4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carboxylic acid by mass spectral interpretation.
  • The study found that GW1516 remained detectable for the longest period in horse plasma among its metabolites.
  • Additionally, the elimination profiles of GW1516, its sulfoxide, and sulfone were established.

Conclusions

  • The research concluded that, for doping control in equine sports, GW1516 should be the primary target monitored. This is because it has a long detection time of around one week, and its reference material is readily available.

Cite This Article

APA
Ishii H, Leung GN, Yamashita S, Yamada M, Kushiro A, Kasashima Y, Okada J, Kawasaki K, Kijima-Suda I. (2020). Doping control analysis of GW1516 in equine plasma using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry. Rapid Commun Mass Spectrom, 34(23), e8920. https://doi.org/10.1002/rcm.8920

Publication

Rapid communications in mass spectrometry : RCM
ISSN: 1097-0231
NlmUniqueID: 8802365
Country: England
Language: English
Volume: 34
Issue: 23
Pages: e8920

Researcher Affiliations

Ishii, Hideaki
  • Drug Analysis Department, Laboratory of Racing Chemistry, 1731-2 Tsuruta-machi, Utsunomiya, Tochigi, 320-0851, Japan.
  • Department of Pharmaceutical Sciences, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.
Leung, Gary Ngai-Wa
  • Drug Analysis Department, Laboratory of Racing Chemistry, 1731-2 Tsuruta-machi, Utsunomiya, Tochigi, 320-0851, Japan.
Yamashita, Shozo
  • Drug Analysis Department, Laboratory of Racing Chemistry, 1731-2 Tsuruta-machi, Utsunomiya, Tochigi, 320-0851, Japan.
Yamada, Masayuki
  • Drug Analysis Department, Laboratory of Racing Chemistry, 1731-2 Tsuruta-machi, Utsunomiya, Tochigi, 320-0851, Japan.
Kushiro, Asuka
  • Equine Research Institute, Research Planning & Coordination Division, JRA, 1400-4 Shiba, Shimotsuke, Tochigi, 329-0412, Japan.
Kasashima, Yoshinori
  • Equine Research Institute, Research Planning & Coordination Division, JRA, 1400-4 Shiba, Shimotsuke, Tochigi, 329-0412, Japan.
Okada, Jun
  • Veterinarian Section, Equine Department, JRA, 6-11-1 Roppongi, Minato-ku, Tokyo, 105-0003, Japan.
Kawasaki, Kazumi
  • Veterinarian Section, Equine Department, JRA, 6-11-1 Roppongi, Minato-ku, Tokyo, 105-0003, Japan.
Kijima-Suda, Isao
  • Drug Analysis Department, Laboratory of Racing Chemistry, 1731-2 Tsuruta-machi, Utsunomiya, Tochigi, 320-0851, Japan.

MeSH Terms

  • Administration, Intranasal
  • Animals
  • Chromatography, Liquid / methods
  • Doping in Sports
  • Female
  • Horses / blood
  • Limit of Detection
  • Linear Models
  • Reproducibility of Results
  • Spectrometry, Mass, Electrospray Ionization / methods
  • Thiazoles / administration & dosage
  • Thiazoles / blood
  • Thiazoles / chemistry
  • Thiazoles / pharmacokinetics

References

This article includes 15 references
  1. Pokrywka A, Cholbinski P, Kaliszewski P, Kowalczyk K, Konczak D, Zembron-Lacny A. Metabolic modulators of the exercise response: Doping control analysis of an agonist of the peroxisome proliferator-activated receptor δ (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR).. J Physiol Pharmacol 2014;65(4):469-476.
  2. Chen W, Gao R, Xie X. A metabolomic study of the PPARδ agonist GW501516 for enhancing running endurance in Kunming mice.. Sci Rep 2015;5:9884.
    doi: 10.1038/srep09884google scholar: lookup
  3. International Federation of Horseracing Authorities. International Agreement.. .
  4. Fédération Équestre Internationale. 2020 Equine Prohibited Substances List.. .
  5. Thevis M, Möller I, Thomas A. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.. Anal Bioanal Chem 2010;396(7):2479-2491.
    doi: 10.1007/s00216-009-3283-xgoogle scholar: lookup
  6. Thevis M, Möller I, Beuck S, Schänzer W. Synthesis, mass spectrometric characterization, and analysis of the PPARδ agonist GW1516 and its major human metabolites: Targets in sports drug testing.. Methods Mol Biol 2013;952:301-312.
    doi: 10.1007/978-1-62703-155-4_22google scholar: lookup
  7. Sobolevsky T, Dikunets M, Sukhanova I, Virus E, Rodchenkov G. Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urine.. Drug Test Anal 2012;4(10):754-760.
    doi: 10.1002/dta.1413google scholar: lookup
  8. Gray B, Viljanto M, Menzies E, Vanhaecke L. Detection of prohibited substances in equine hair by ultra-high performance liquid chromatography-triple quadrupole mass spectrometry: Application to doping control samples.. Drug Test Anal 2018;10(7):1050-1060.
    doi: 10.1002/dta.2367google scholar: lookup
  9. Nishimura K, Nakano N, Chowdhury VS. Effect of PPARβ/δ agonist on the placentation and embryo-fetal development in rats.. Birth Defects Res B Dev Reprod Toxicol 2013;98(2):164-169.
    doi: 10.1002/bdrb.21052google scholar: lookup
  10. Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.. Expert Opin Pharmacother 2014;15(4):493-503.
    doi: 10.1517/14656566.2014.876992google scholar: lookup
  11. Ishii H, Yamaguchi H, Mano N. Expanding the versatility of a quantitative determination range adjustment technique using in-source CID in LC/MS/MS.. Chromatography 2017;38(2):59-63.
    doi: 10.15583/jpchrom.2017.004google scholar: lookup
  12. Ishii H, Yamaguchi H, Mano N. Shifting the linear range in electrospray ionization by in-source collision-induced dissociation.. Chem Pharm Bull (Tokyo) 2016;64(4):356-359.
    doi: 10.1248/cpb.c15-00741google scholar: lookup
  13. Takasaki S, Tanaka M, Kikuchi M. Simultaneous analysis of oral anticancer drugs for renal cell carcinoma in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry.. Biomed Chromatogr 2018;32(6):e4184.
    doi: 10.1002/bmc.4184google scholar: lookup
  14. Ishii H, Shimada M, Yamaguchi H, Mano N. A simultaneous determination method for 5-fluorouracil and its metabolites in human plasma with linear range adjusted by in-source collision-induced dissociation using hydrophilic interaction liquid chromatography-electrospray ionization-tandem mass spectrometry.. Biomed Chromatogr 2016;30(11):1882-1886.
    doi: 10.1002/bmc.3743google scholar: lookup
  15. Takeda A, Nakata M, Kijima-Suda I, Tanaka H. Trial for ionisation enhancement in negative ion electrospray ionisation and rapid screening of acid drugs by liquid chromatography/mass spectrometry.. In: Proceedings of the 16th International Conference of Racing Analysts and Veterinarians Tokyo, Japan, 2006. Vol.2007 PA: R & W Communications:239-245.

Citations

This article has been cited 3 times.
  1. Ishii H, Shibuya M, Kusano K, Sone Y, Kamiya T, Wakuno A, Ito H, Miyata K, Sato F, Kuroda T, Yamada M, Leung GN. Generic approach for the discovery of drug metabolites in horses based on data-dependent acquisition by liquid chromatography high-resolution mass spectrometry and its applications to pharmacokinetic study of daprodustat. Anal Bioanal Chem 2022 Nov;414(28):8125-8142.
    doi: 10.1007/s00216-022-04347-2pubmed: 36181513google scholar: lookup
  2. Ishii H, Shibuya M, Kusano K, Sone Y, Kamiya T, Wakuno A, Ito H, Miyata K, Sato F, Kuroda T, Yamada M, Leung GN. Pharmacokinetic Study of Vadadustat and High-Resolution Mass Spectrometric Characterization of its Novel Metabolites in Equines for the Purpose of Doping Control. Curr Drug Metab 2022;23(10):850-865.
    doi: 10.2174/1389200223666220825093945pubmed: 36017833google scholar: lookup
  3. Ishii H, Shigematsu R, Takemoto S, Ishikawa Y, Mizobe F, Nomura M, Arima D, Kunii H, Yuasa R, Yamanaka T, Tanabe S, Nagata SI, Yamada M, Leung GN. Quantification of osilodrostat in horse urine using LC/ESI-HRMS to establish an elimination profile for doping control. Bioanalysis 2024;16(17-18):947-958.
    doi: 10.1080/17576180.2024.2385848pubmed: 39235065google scholar: lookup
Subscribe to our newsletter
Join 100,127 horse owners like you who receive our email updates on horse health and nutrition.